News

Tom Ryder Joins Focused Ultrasound Foundation Board of Directors

CHARLOTTESVILLE, VA – Thomas O. Ryder, an investor, entrepreneur, and retired corporate executive, was elected to the Focused Ultrasound Foundation’s Board of Directors at their March 1 meeting.

Ryder has served as Chairman and CEO of the Reader’s Digest Association and President of American Express’s Travel Related Services International, Merchant Services Worldwide, and American Express Publishing Worldwide divisions.

He has experience in the publishing industry, having worked at Time Inc., CBS, and Education Today Company, Inc. where he was co-founder and CEO.

Ryder has also served on numerous boards, including at Amazon for 20 years, during which time he was audit committee chairman and the first lead independent director.

Other previous board appointments have included Starwood Hotels, RPX Corporation, Startek Corp, American Express International Bank, and Virgin Mobile – where he was Chairman.

He is also a prolific writer on the subjects of food and wine.

“Tom brings his unsurpassed skills and experience to the Foundation’s leadership team,” said Foundation Chairman Neal F. Kassell, MD. “He will help to facilitate our efforts to overcome barriers and take advantage of opportunities to shorten the time for focused ultrasound to become a global standard of care.”

Ryder is also an essential tremor patient who underwent focused ultrasound therapy for the disorder in 2021.

“Focused ultrasound fixed a major problem I had with essential tremor and changed my life,” he explains. “I truly hope my tenure on the Foundation Board of Directors will give me the opportunity to share that miracle with others in similar need.”

Read more here.

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by